Gestational Treatment With Ursodeoxycholic Acid Compared to Placebo to Reduce Severity of Gestational Diabetes Mellitus Diagnosed at 24-28 Weeks' Gestation

Gestational Diabetes Clinical Trial

— GUARDS  

Official title:

Gestational Treatment With Ursodeoxycholic Acid Compared to Placebo to Reduce Severity of Gestational Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06127355
• Other study ID #: IMIB-GU-2019-02
• Status: Completed
• Phase: Phase 3
• Start date: March 3, 2021
• Est. completion date: May 10, 2022

Study information

• Verified date: November 2023
• Source: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial will compare the influence of treatment with ursodeoxycholic acid (UDCA) compared to placebo on glycaemic control (primary outcome) in women with GDM after a positive diagnosis at 24-28 weeks of gestation.

The investigators will evaluate maternal and fetal lipid and glucose metabolism. Neonatal health outcomes will also be studied, including the rate of LGA. UDCA is used to treat the commonest liver disease of pregnancy, intrahepatic cholestasis of pregnancy (ICP), and has good safety data to support its use in pregnancy 52-57 ., it means, no studies reported any increase in adverse outcomes associated with UDCA treatment. It is noteworthy that in the largest study 52, 8 serious adverse events were reported, 6 of which were in the placebo group, and none were considered to be related to the trial intervention. There were 72 adverse events: 31 in the ursodeoxycholic acid group and 41 in the placebo group. The same number of patients in each group (n=10) reported adverse events related to gastrointestinal disorders.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 113
• Est. completion date: May 10, 2022
• Est. primary completion date: February 9, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women with GDM diagnosed at 24-28 weeks' gestation in accordance with Spanish guidelines in accordance with NDDG criteria, i.e. two or more glucose concentrations (fasting: = 5.8 mmol/L (105 mg/dL), 1 h: =10.6 mmol/L, (190 mg/dL) 2 h: =9.2 mmol/L (165 mg/dL), 3 h: = 8.1 mmol/L (145 mg/dL)) after a standard 100g OGTT, two fasting blood glucose levels = 126 mg/dl, on different days, or at random = 200 mg/dL or a plasma glucose value greater than 200 mg/dL after OSullivan test

• Planned antenatal care at the same centre (i.e. not planning to move before delivery).

• Singleton pregnancy.

• Informed and written consent.

Exclusion Criteria:

• Age <18 years;

• Multiple pregnancy in current pregnancy;

• Unconscious or very ill;

• Serious mental illness;

• Learning difficulties;

• Not fluent in local language and absence of interpreter.

• Severe congenital anomaly on ultrasound

• Previous diagnosis of diabetes outside of pregnancy

• Significant pre-pregnancy comorbidities that increase risk in pregnancy, for example renal failure, severe liver disease, transplantation, cardiac failure, psychiatric conditions requiring in-patient admission (<1 year)

• Significant co-morbidity in the current pregnancy, nephropathy (estimated GF<60ml/min), other physical or psychological conditions likely to interfere with the conduct of the study and/or interpretation of the trial results

• Participating in another intervention study that will influence the outcome of this trial (to be advised by CI or PI).

• Known allergy/hypersensitivity/intolerance to the active substance or excipients.

• Hypersensitivity to Ursodexosolic acid or to the following excipients: Magnesium stearate, cellulose powder, colloidal silica and sodium carboxymethyl starch, gelatin, titanium dioxide, quinoline yellow, orange yellow S, indigotine.

• Patients with a non-functioning gallbladder, in patients with calcified cholesterol stones, radio-opaque stones, radiolucent gallbladder stones.

• Gastric or duodenal ulcer.

• Liver or intestinal disorders that interfere with the enterohepatic circulation: acute cholecystitis that does not subside, cholangitis, biliary obstruction, pancreatitis due to stones, patients with gastrointestinal-biliary fistula.

• Breastfeeding

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes, Gestational
• Gestational Diabetes

Intervention

Drug:
• 500 mg of ursodeoxycholic acid (UDCA)
Administration of 500 mg of ursodeoxycholic acid (UDCA) /day

Other:
• 500 mg of Placebo
Administration of 500 mg of placebo /day

Locations

Country	Name	City	State
Spain	Hospital Clínico Universitario Virgen de la Arrixaca	Murcia

Sponsors (1)

Lead Sponsor	Collaborator
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maternal fasting glucose concentration at 36 weeks	aiming to maintain all capillary glucose levels between 3.9-7.8mmol/l (70 - 140 mg/dL). The specific pre- and post-meal self-monitored blood glucose (SMBG) targets are =5.3mmol/L before breakfast (95 mg/dL), =7.8mmol/L 1-hr post meal (140 mg/dL) and =6.7mmol/L (120 mg/dL) 2-hr post meal.	Up to 36 weeks
Secondary	Proportion of women requiring insulin treatment	Number of women with insuline treatment	Up to 36 weeks
Secondary	Proportion of delivery type	Mode of delivery (rates of primary & repeat CS, elective & emergency	Up to 40 weeks
Secondary	Gestational age at delivery, frequency of preterm delivery	Age of patient	Up to 40 weeks
Secondary	Infant birth weight	Weight in kg	Up to 40 weeks